Penumbra, Inc. $PEN Stock Holdings Raised by Capital World Investors

Capital World Investors raised its stake in Penumbra, Inc. (NYSE:PEN) by 2.6% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 426,456 shares of the company’s stock after purchasing an additional 10,724 shares during the period. Capital World Investors owned 1.09% of Penumbra worth $132,589,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Farther Finance Advisors LLC increased its position in shares of Penumbra by 27.1% in the 4th quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock worth $55,000 after purchasing an additional 38 shares during the last quarter. Swiss Life Asset Management Ltd increased its position in shares of Penumbra by 2.3% in the 4th quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock worth $537,000 after purchasing an additional 39 shares during the last quarter. Abbot Financial Management Inc. increased its position in shares of Penumbra by 1.3% in the 3rd quarter. Abbot Financial Management Inc. now owns 3,254 shares of the company’s stock worth $824,000 after purchasing an additional 42 shares during the last quarter. Glenview Trust Co increased its position in shares of Penumbra by 5.0% in the 3rd quarter. Glenview Trust Co now owns 904 shares of the company’s stock worth $229,000 after purchasing an additional 43 shares during the last quarter. Finally, Keybank National Association OH increased its position in shares of Penumbra by 1.2% in the 4th quarter. Keybank National Association OH now owns 3,705 shares of the company’s stock worth $1,152,000 after purchasing an additional 43 shares during the last quarter. Institutional investors own 88.88% of the company’s stock.

Penumbra Trading Down 0.1%

Penumbra stock opened at $320.28 on Tuesday. The company has a quick ratio of 3.95, a current ratio of 6.02 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $326.54 and a two-hundred day moving average price of $326.64. The firm has a market capitalization of $12.60 billion, a price-to-earnings ratio of 73.80, a PEG ratio of 1.96 and a beta of 0.71. Penumbra, Inc. has a 52-week low of $221.26 and a 52-week high of $362.41.

Penumbra (NYSE:PEN) last posted its earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.06 by ($0.24). The firm had revenue of $374.76 million for the quarter, compared to analyst estimates of $370.47 million. Penumbra had a net margin of 11.76% and a return on equity of 10.87%. The company’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.83 earnings per share. Sell-side analysts expect that Penumbra, Inc. will post 5.08 earnings per share for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Citigroup dropped their target price on shares of Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Wall Street Zen raised shares of Penumbra to a “hold” rating in a research report on Saturday, May 9th. UBS Group reaffirmed a “neutral” rating and set a $374.00 price objective on shares of Penumbra in a research report on Thursday, February 26th. Finally, Evercore reaffirmed an “outperform” rating and set a $335.00 price objective on shares of Penumbra in a research report on Thursday, May 7th. Three research analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $361.33.

Insider Transactions at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 100 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $328.22, for a total transaction of $32,822.00. Following the completion of the transaction, the director directly owned 8,719 shares of the company’s stock, valued at $2,861,750.18. The trade was a 1.13% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 2.90% of the stock is owned by insiders.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.